Krystal Biotech (KRYS) Gains 36% Year to Date: Here's Why [Yahoo! Finance]
Krystal Biotech, Inc. (KRYS)
Last krystal biotech, inc. earnings: 11/4 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.krystalbio.com/investors
Company Research
Source: Yahoo! Finance
4.3%. This was due to the strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress. In May 2023, the FDA approved Vyjuvek, the first ever redosable gene therapy for treating patients aged six months or older with dystrophic epidermolysis bullosa (DEB). DEB is a rare and severe monogenic disease that affects the skin and mucosal tissues. It is caused by one or more mutations in a gene called COL7A1. Image Source: Zacks Investment Research The drug, launched in the second quarter of 2023, generated sales of $45.3 in the first quarter of 2024. Krystal has made steady progress, securing access and reimbursement for Vyjuvek since its launch. In January 2024, the U.S. Centers for Medicare & Medicaid Services assigned a permanent and product-specific J-code (J3401) for Vyjuvek, effective Jan 1. As of April 2024, positive access was achieved for 96% of lives covered under commercial and Medicaid plans. In the same month, Krystal secured more than 330 reim
Show less
Read more
Impact Snapshot
Event Time:
KRYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRYS alerts
High impacting Krystal Biotech, Inc. news events
Weekly update
A roundup of the hottest topics
KRYS
News
- Krystal Biotech (KRYS) Surged as it Beat the Streat Estimates with Wide Margin [Yahoo! Finance]Yahoo! Finance
- Krystal Biotech, Virtu, StepStone, Cactus, Tidewater to join S&P 600 [Seeking Alpha]Seeking Alpha
- KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600PR Newswire
- Krystal Biotech to Present at Goldman Sachs 45th Annual Global Healthcare ConferenceGlobeNewswire
- Is Krystal Biotech, Inc. (NASDAQ:KRYS) the Premier Gene Therapy Stock for Your Portfolio? [Yahoo! Finance]Yahoo! Finance
KRYS
Earnings
- 5/6/24 - Miss
KRYS
Sec Filings
- 6/11/24 - Form 4
- 6/11/24 - Form 4
- 6/11/24 - Form 144
- KRYS's page on the SEC website